# APR - 1 2005

# 510K SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: 050419

# COMPANY/CONTACT PERSON

Seradyn, Inc   
7998 Georgetown Road, Suite 1000   
Indianapolis, IN 46268

Establishment registration No: 1836010

Jack Rogers Manager of Regulatory Affairs Telephone: (317) 610-3823 Fax: (317) 610-0018

# DATE PREPARED

February 17, 2005

# DEVICE NAME

Trade Name: QMS ® Vancomycin Common Name: Vancomycin Test System Device Classification: 21 CFR 862.3950; Class II

# INTENDED USE

The $\mathsf { Q M S } ^ { \otimes }$ Vancomycin assay is intended for the quantitative determination of vancomycin in human serum or plasma on the Hitachi 717 analyzer.

The results obtained are used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to ensure appropriate therapy.

# LEGALLY MARKETED DEVICE TO WHICH EQUIVALENCY IS CLAIMED

${ \sf T D X } ^ { \circledast }$ Vancomycin (K813218)

# DESCRIPTION OF DEVICE

The QMS® Vancomycin assay is a homogeneous particle-enhanced turbidimetric immunoassay.The assay is based on competition between drug in the sample and drug coated onto a microparticle for antibody binding sites of the vancomycin antibody reagent. The vancomycin-coated microparticle reagent is rapidly agglutinated in the presence of the anti-vancomycin antibody reagent and in the absence of any competing in he sapleThe atebsorbancechange is meau hoerically, an i direcly prooal to the rate of agglutination of the particles. When a sample containing vancomycin is added, the agglutination reaction is partally inhibited,slowingdown therateof absorbance hangeAconcentration dependent classicagglutination inhibition curve can beobtained, with maximum rateof agglutination t the lowest vancomycin concentration and the lowest agglutination rate at the highest vancomycin concentration.

The assay consists of reagents R1: vancomycin monoclonal antibody and R2: vancomycin-coated micoartices. si-evel t of ® Vanoycin Calirators hrogh is se o calirate the y.

# COMPARISON OF TECHNOLOGICAL CHARACTERISTICS

<table><tr><td rowspan=1 colspan=1>DeviceSeradyn QMS® Vancomycin</td><td rowspan=1 colspan=1>PredicateAbbott TDx®/TDxFLx® Vancomycin</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The QMS® Vancomycin assay is intendedfor the quantitative determination ofvancomycin in human serum or plasma onthe Hitachi 717 analyzer.</td><td rowspan=1 colspan=1>The TDx/TDxFLx Vancomycin assay is areagent system for the quantitativemeasurement of vancomycin, an antibioticdrug, in serum or plasma.</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>The results obtained are used in thediagnosis and treatment of vancomycinoverdose and in monitoring levels ofvancomycin to ensure appropriatetherapy.</td><td rowspan=1 colspan=1>The measurements obtained are used in thediagnosis and treatment of vancomycinoverdose and in monitoring levels ofvancomycin to ensure appropriate therapy.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogeneous particle-enhancedturbidimetric immunoassay (particleagglutination)</td><td rowspan=1 colspan=1>Fluorescence Polarization Immunoassay(FPIA)</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-Vancomycin Antibody Reagent(R1) in buffers containing proteinstabilizersVancomycin-coated MicroparticleReagent (R2) in buffer containingsurfactant as stabilizers with sodiumazide</td><td rowspan=1 colspan=1>Three (3) Reagent System:Vancomycin Antiserum in buffer withprotein stabilizersVancomycin Fluorescein Tracer in buffercontaining surfactants and proteinstabilizers with sodium azidePretreatment Solution. Surfactants inbuffer containing protein stabilizers withsodium azide</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Seradyn QMS Vancomycin Calibrators -six levels</td><td rowspan=1 colspan=1>TDx/TDxFLx Vancomycin Calibrators -six levels</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0 - 100 μg/mL</td><td rowspan=1 colspan=1>0 - 100 μg/mL</td></tr></table>

# SUMMARY OF CLINICAL TESTING

# Precision

A precision study was performed using the National Committe for Clinical Laboratory Standards (NCCLS) guideline EP5-A: Evaluation of Precision Performance of Clinical Chemistry Devices.Representative results are shown below.   

<table><tr><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>BETWEEN DAY</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Low Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>7.57</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>3.59</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>5.70</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>8.84</td></tr><tr><td rowspan=1 colspan=1>Mid Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>20.79</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>2.44</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>3.30</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>4.66</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>6.21</td></tr><tr><td rowspan=1 colspan=1>High Control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>33.65</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>2.37</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>3.54</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>2.83</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>5.12</td></tr></table>

# Accuracy

Accuracy by Recovery was determined by spiking USP traceable vancomycin into human serum negative for the drug to achieve concentrations across the assay rangeThe samples were analyzed in trplicat the QMs Vancomycin assay. Representative results are shown below.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μG/ML)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>Rep 3</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>cv</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>100.00</td><td rowspan=1 colspan=1>93.50</td><td rowspan=1 colspan=1>95.68</td><td rowspan=1 colspan=1>95.87</td><td rowspan=1 colspan=1>95.02</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>95.02</td></tr><tr><td rowspan=1 colspan=1>75.00</td><td rowspan=1 colspan=1>73.82</td><td rowspan=1 colspan=1>76.14</td><td rowspan=1 colspan=1>69.76</td><td rowspan=1 colspan=1>73.24</td><td rowspan=1 colspan=1>3.23</td><td rowspan=1 colspan=1>4.41</td><td rowspan=1 colspan=1>97.65</td></tr><tr><td rowspan=1 colspan=1>50.00</td><td rowspan=1 colspan=1>52.45</td><td rowspan=1 colspan=1>50.66</td><td rowspan=1 colspan=1>53.64</td><td rowspan=1 colspan=1>52.25</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>104.50</td></tr><tr><td rowspan=1 colspan=1>37.50</td><td rowspan=1 colspan=1>42.15</td><td rowspan=1 colspan=1>38.36</td><td rowspan=1 colspan=1>38.60</td><td rowspan=1 colspan=1>39.70</td><td rowspan=1 colspan=1>2.12</td><td rowspan=1 colspan=1>5.35</td><td rowspan=1 colspan=1>105.88</td></tr><tr><td rowspan=1 colspan=1>25.00</td><td rowspan=1 colspan=1>27.30</td><td rowspan=1 colspan=1>28.71</td><td rowspan=1 colspan=1>26.95</td><td rowspan=1 colspan=1>27.65</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>3.37</td><td rowspan=1 colspan=1>110.61</td></tr><tr><td rowspan=1 colspan=1>17.50</td><td rowspan=1 colspan=1>16.53</td><td rowspan=1 colspan=1>18.45</td><td rowspan=1 colspan=1>17.36</td><td rowspan=1 colspan=1>17.45</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>5.52</td><td rowspan=1 colspan=1>99.70</td></tr><tr><td rowspan=1 colspan=1>10.00</td><td rowspan=1 colspan=1>9.20</td><td rowspan=1 colspan=1>9.39</td><td rowspan=1 colspan=1>9.22</td><td rowspan=1 colspan=1>9.27</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>92.70</td></tr><tr><td rowspan=1 colspan=1>7.50</td><td rowspan=1 colspan=1>6.79</td><td rowspan=1 colspan=1>6.93</td><td rowspan=1 colspan=1>6.78</td><td rowspan=1 colspan=1>6.83</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>91.11</td></tr><tr><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>4.89</td><td rowspan=1 colspan=1>4.90</td><td rowspan=1 colspan=1>4.97</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>99.33</td></tr><tr><td rowspan=1 colspan=7>Mean Percent Recovery</td><td rowspan=1 colspan=1>99.61</td></tr></table>

# Linearity

Linearity by Dilution was determined by a study based on the NCCLS guideline EP6-A:Evaluation of the Linearity of Quantitative Measurement. Representative results are shown below.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μg/mL)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>Rep 3</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>75.00</td><td rowspan=1 colspan=1>76.68</td><td rowspan=1 colspan=1>74.77</td><td rowspan=1 colspan=1>75.85</td><td rowspan=1 colspan=1>75.77</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>101.02</td></tr><tr><td rowspan=1 colspan=1>37.50</td><td rowspan=1 colspan=1>37.45</td><td rowspan=1 colspan=1>36.86</td><td rowspan=1 colspan=1>37.30</td><td rowspan=1 colspan=1>37.20</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.82</td><td rowspan=1 colspan=1>99.21</td></tr><tr><td rowspan=1 colspan=1>17.50</td><td rowspan=1 colspan=1>17.03</td><td rowspan=1 colspan=1>16.54</td><td rowspan=1 colspan=1>16.68</td><td rowspan=1 colspan=1>16.75</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>95.71</td></tr><tr><td rowspan=1 colspan=1>7.50</td><td rowspan=1 colspan=1>7.37</td><td rowspan=1 colspan=1>7.36</td><td rowspan=1 colspan=1>7.25</td><td rowspan=1 colspan=1>7.33</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>97.69</td></tr><tr><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>3.15</td><td rowspan=1 colspan=1>2.64</td><td rowspan=1 colspan=1>2.72</td><td rowspan=1 colspan=1>2.68</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>107.20</td></tr><tr><td rowspan=1 colspan=7>2.50Mean Percent Recovery</td><td rowspan=1 colspan=1>100.17</td></tr></table>

![](images/6c837dfab2454bfed9ac84bc3e2332b7453c8ba1493fb0d387b929c44790a8a0.jpg)

# Sensitivity

The Analytical Sensitivity or Least Detectable Dose (LDD) of the assay is defined as the concentration at which the lowest concentration is distinguishable from zero with $9 5 \%$ confidence.

The LDD was calculated using the following formula:

# Where:

Zero Cal $=$ Cal A $( 0 \mu g / m L )$ . SD Zero Cal $\Bumpeq$ standard deviation of the duplicate determinations D 15t Non-Zero Cal $=$ Cal 8 $( 5 \mu 9 / \mu \nu \nu )$

The LDD was determined to be $0 . 4 6 ~ { \mu \mathrm { g / m L } }$ , supporting a claim of $0 . 5 5 \mu { \bf { g } } / m L$ .

# Specificity

In vivo, vancomycin degrades to its metabolite CDP-I (crystalline degradation product-l).

Percent cross-reactivity was tested with the metobolite at $1 0 0 \ \mu \mathrm { g / m l }$ in serum containing $2 5 ~ \mu \ g / m L$ vancomycin and was determined according to NCCLS guidance EP7-A: Interference Testing in Clinical Chemistry.

Results show that CDP-I has $< 5 \%$ cross-reactivity.

# Interferences

Interference studies were conducted using NCCLS Guideline EP7-A: Interference Testing in Clinical Chemistry.

# 1) Endogenous Substances

The following compounds, when tested at the concentrations indicated, resulted in less than $10 \%$ error in detecting vancomycin.

<table><tr><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>InterferentConcentration</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Target(No Interferent)μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/mL</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>10 g/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26.61</td><td rowspan=1 colspan=1>24.92</td><td rowspan=1 colspan=1>93.64</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>70 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26.98</td><td rowspan=1 colspan=1>27.00</td><td rowspan=1 colspan=1>100.07</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26.61</td><td rowspan=1 colspan=1>25.97</td><td rowspan=1 colspan=1>97.58</td></tr><tr><td rowspan=1 colspan=1>IgG(Gamma Globulin)</td><td rowspan=1 colspan=1>6 g/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26.61</td><td rowspan=1 colspan=1>25.90</td><td rowspan=1 colspan=1>97.34</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1150 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23.12</td><td rowspan=1 colspan=1>21.18</td><td rowspan=1 colspan=1>91.64</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>500 units/mL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>26.61</td><td rowspan=1 colspan=1>26.46</td><td rowspan=1 colspan=1>99.44</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10.16</td><td rowspan=1 colspan=1>9.41</td><td rowspan=1 colspan=1>92.62</td></tr><tr><td rowspan=1 colspan=1>RheumatoidFactor</td><td rowspan=1 colspan=1>1100 IU/mL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7.19</td><td rowspan=1 colspan=1>6.70</td><td rowspan=1 colspan=1>93.23</td></tr></table>

# HAMA

As with any assay employing mouse antibodies, the possibility exists for interference by human antimouse antibodies (HAMA) in the sample, which could cause falsely elevated results.

HAMA Type-1 and Type-2 samples were spiked to achieve $2 5 \ \mu { \sf g } / \sf m L$ vancomycin. The mean recovery for each (Type-1 and Type-2) of the triplicate HAMA samples was compared to the mean recovery of each respective Control (normal human serum). Representative results are shown below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Rep 1μg/mL</td><td rowspan=1 colspan=1>Rep 2μg/mL</td><td rowspan=1 colspan=1>Rep 3μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/mL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>HAMAType-1</td><td rowspan=1 colspan=1>29.45</td><td rowspan=1 colspan=1>28.51</td><td rowspan=1 colspan=1>26.86</td><td rowspan=1 colspan=1>28.27</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>4.63</td><td rowspan=2 colspan=1>105.31</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>27.75</td><td rowspan=1 colspan=1>27.05</td><td rowspan=1 colspan=1>25.74</td><td rowspan=1 colspan=1>26.85</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>3.80</td></tr><tr><td rowspan=1 colspan=1>HAMAType-2</td><td rowspan=1 colspan=1>29.36</td><td rowspan=1 colspan=1>30.20</td><td rowspan=1 colspan=1>29.43</td><td rowspan=1 colspan=1>29.66</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.58</td><td rowspan=2 colspan=1>103.91</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>29.67</td><td rowspan=1 colspan=1>28.13</td><td rowspan=1 colspan=1>27.84</td><td rowspan=1 colspan=1>28.55</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>3.43</td></tr></table>

# Common Co-Administered Drugs

Cross-reactivity was tested with drugs that are routinely administered with vancomycin. Testing also determined whether these compounds affect the quantitation of vancomycin concentrations. Crossreactants were analyzed at $5 0 0 \mu g / m L$ in a vancomycin spiked serum pool at $2 5 \mu \ g / \mu \mu$ .The samples were assayed and the vancomycin concentrations of the spiked samples were compared to a control serum. All of the following cross-reactants showed ${ < } 0 . 3 \%$ cross-reactivity.

<table><tr><td colspan="3">Cross-Reactants</td></tr><tr><td>Acetaminophen</td><td>Ethambutol</td><td>Oxytetracycline</td></tr><tr><td>Amikacin</td><td>5-Fluorocytosine</td><td>Penicillin G</td></tr><tr><td>Amphotericin B</td><td>Furosemide</td><td>Penicillin V</td></tr><tr><td>Ampicillin</td><td>Fusidic Acid</td><td>Phenacetin</td></tr><tr><td>Bendroflumethiazide</td><td>Gentamicin</td><td>Nitrofurantoin</td></tr><tr><td>Caffeine</td><td>Hydrochlorothiazide</td><td>Prednisolone</td></tr><tr><td>Carbenicillin</td><td>Ibuprofen</td><td>Prednisone</td></tr><tr><td>Cefamandole Nafate</td><td>Isoniazide</td><td>Rifampicin</td></tr><tr><td>Cefazolin</td><td>Kanamycin A</td><td>Salicyclic Acid</td></tr><tr><td>Cephalexin</td><td>Kanamycin B</td><td>Sisomycin</td></tr><tr><td>Cephalosporin C</td><td>Lincomycin</td><td>Spectinomycin</td></tr><tr><td>Cephalothin</td><td>Methotrexate</td><td>Sulfadiazine</td></tr><tr><td>Chloramphenicol</td><td>Methylprednisolone</td><td>Sulfamethoxazole</td></tr><tr><td>Chlorothiazide</td><td>Nalidixic Acid</td><td>Sulfisoxazole</td></tr><tr><td>Clindamycin</td><td>Naproxen</td><td>Tetracycline</td></tr><tr><td>Erythromycin</td><td>Neomycin Sulfate</td><td>Tobramycin</td></tr><tr><td>Ethacrynic Acid</td><td>Niacin</td><td>Trimethoprim</td></tr></table>

# Structurally Related Drug

The cross-reactivity of the QMs® Vancomycin antibody to teicoplanin, a structurally similar compound, was examined. Teicoplanin was spiked into human serum containing $2 5 \mu \ g / \mu \mathrm { u } L$ vancomycin and tested in the QMS Vancomycin assay. Representative results are shown below.

$\%$ cross-reactivity $=$ measured concentration of vancomycin x 100 teicoplanin concentration   

<table><tr><td>Teicoplanin Concentration (μg/mL)</td><td>% Cross- Reactivity</td></tr><tr><td>100</td><td>0.68</td></tr><tr><td>50</td><td>0.29</td></tr><tr><td>25</td><td>0.20</td></tr><tr><td>10</td><td>0.03</td></tr></table>

# Method Comparison

A study was conducted according to NCCLS Guideline $E P 9 { \cdot } A ;$ Method Comparison and Bias Estimation Using Patient Samples to compare accuracy of recovery of vancomycin in serum assayed by the $\mathsf { Q M S } ^ { \odot }$ Vancomycin assay to the Abbott ${ \mathsf { T } } { \mathsf { D } } \mathbf { x } ^ { \mathfrak { O } }$ Vancomycin assay.

Serum samples, ranging from 0.04 to $1 0 0 \ \mu g / m L$ vancomycin, were first tested using Abbott's TDx Vancomycin assay. The same samples were then tested by the QMS Vancomycin assay on Hitachi 717 analyzers using two reagent lots on two separate calibration curves.

Mean values for the TDx reference method were plotted against those for the QMS on Hitachi 717. The results using Passing-Bablok Linear Regression are:

$$
\begin{array} { r l } & { \mathsf { N } = 1 4 6 } \\ & { \mathsf { S l o p e } = 1 . 0 3 1 } \\ & { \mathsf { y - i n t e r c e p t } = 1 . 1 1 5 } \\ & { \mathsf { R } ^ { 2 } = 0 . 9 7 0 } \end{array}
$$

Results show excellent correlation between the two assays.

# On-Board Stability

# Calibration Curve stability

Calibration curve stability for a period of 31 days is supported by the data.

# Reagent On-Board Stability

A 62 day on-board reagent stability claim is supported by the data.

# CONCLUSION

As summarized above, the QMS® Vancomycin assay is substantially equivalent to the Abbott $T D x ^ { \otimes } / \tilde { 1 } D x F L x ^ { \otimes }$ Vancomycin assay.Substantial equivalence has been demonstrated through performance testing to verify that the device functions as intended and that design specifications have been satisfied.

# APR - 1 2005

Mr. Jack Rogers, MS, RAC Manger of Regulatory Affairs Seradyn, Inc.   
7998 Georgetown Road   
Suite 1000   
Indianapolis, IN 46268-5620

Re: k050419 Trade/Device Name: QMS $^ \mathrm { \textregistered }$ Vancomycin Regulation Number: 21 CFR 862.3950 Regulation Name: Vancomycin test system Regulatory Class: Class II Product Code: LEH Dated: February 17, 2005 Received: February 18, 2005

Dear Mr. Rogers

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA mav publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

![](images/1888047d60c542fe59e12d1ec4c25d00493052153d3f23b2ecd10cef4469ab32.jpg)

Jean M. Cooper, MS, D.V.M.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (i known): K050419

Device Name: QMS® Vancomycin

# Indications for Use:

The $\mathsf { Q M S } ^ { \circledast }$ Vancomycin assay is intended for the quantitative determination of.   
vancomycin in human serum or plasma on the Hitachi 717 analyzer.

The results obtained are used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to ensure appropriate therapy.

# (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Allt   
Division Sign-Off)   
Division of Clinical Laboratory Deviees 510(k) Number K050419

Page 1 of